The efficacy of early versus late treatment with acyclovir and valaciclovir on zoster-associated pain was assessed from two databases (1076 patients) that were compiled from randomized trials. Early treatment was started õ48 h and late treatment was started 48 -72 h after the onset of cutaneous herpes zoster. Median times to complete resolution of zoster-associated pain were 28 and 62 days, respectively, for patients ( §18 years of age) treated with acyclovir and placebo within 48 h (hazard ratio [HR], 1.68; 95% confidence limit [95% CL], 1.19, 2.38) and 28 and 58 days, respectively, for those treated later (HR, 2.20; 95% CL, 1.03, 4.71). In the valaciclovir versus acyclovir study (in patients §50 years of age), the corresponding figures were 44 and 51 days for patients treated early (HR, 1.28; 95% CL, 1.03, 1.60) and 36 and 48 days for those treated later (HR, 1.40; 95% CL, 1.04, 1.87). Acyclovir significantly shortened the time to complete resolution of zosterassociated pain compared with placebo (and valaciclovir was superior to acyclovir in this regard) even when therapy was delayed up to 72 h after rash onset.
Herpes zoster (HZ) results from reactivation of varicella-
Most controlled clinical trials of antiviral drugs for HZ in otherwise immunocompetent individuals have enrolled patients zoster virus (VZV) in the dorsal root ganglion and is the most common sensory neurologic disease in the elderly. Although within 72 h from rash onset [3 -9] . The efficacy of acyclovir on rash healing was shown to be most marked when treatment the disease can occur at any age, in the otherwise immunocompetent individual the risk of developing HZ substantially inwas started within 48 h of rash onset [4] ; however, given the complex pathophysiology of acute pain and the postherpetic creases over the age of 50 years: it has been estimated that 50% of persons who reach the age of 85 years will have suffered at neuralgia of HZ and the possibility of differing degrees of penetration of antiviral agents into dermatologic and neurologic least one attack of HZ [1] .
The most troublesome symptom of HZ is pain, which occurs tissues, the time course for antiviral efficacy on rash and on pain should not be assumed to be comparable. It is possible, in most patients and, particularly in the elderly, often persists after the cutaneous manifestations of the disease have healed.
therefore, that limiting antiviral usage to early in the course of the rash may deny patients potential benefits on pain resolution. The pathophysiology of the pain of HZ is complex. Replication of VZV within the neurons causes an acute neuritis, and this, Although patients who experience chronic pain will also in turn, initiates changes within the central nervous system, have suffered acute pain (of a different pathophysiology), these leading to potentially chronic neuralgia. Because the nerve overlap to a considerable extent; thus, patients regard their pain damage or malfunction (or both) triggered by VZV replication as a continuum. For this reason and also because it avoids a occurring early in acute HZ is responsible for the pathophysiolpossibility of introduction of inherent bias, many have adopted ogy of the more persistent pain, therapy with antivirals to limit the term zoster-associated pain for the primary pain end-point the subsequent pain of HZ must be started during the period measurement in clinical trials evaluating antiviral agents in HZ of viral replication [2] . Prompt presentation and diagnosis is [10] . Two large databases (1076 patients) have been generated therefore critical for effective relief of symptoms and for stopfrom the controlled clinical trials of acyclovir and valaciclovir ping further virus replication. This is often not achieved since in the treatment of acute HZ. The trials measured the duration most patients and their medical attendants do not recognize the of zoster-associated pain as a primary end point [9, 11] . prodromal pain of HZ for what it is and only present or diagThe first database comprised results for all patients in the nose the condition once the rash appears.
three placebo-controlled studies of oral acyclovir in which the recommended doses (800 mg five times daily) were used and the time to complete cessation of pain was assessed. The results showed that acyclovir was significantly better than a placebo
Informed consent was obtained from all patients, and human experimentation in speeding resolution of zoster-associated pain (hazard ratio guidelines of the investigators' institutions were followed in the conduct of the clinical research on which this analysis is based.
[HR], 1. In the present study, these databases were analyzed further years in study 1 (although ú90% were §50) and 68 years in study 2. At least 60% of patients in each dataset began treatto determine the efficacy of acyclovir or valaciclovir therapy on the duration of zoster-associated pain when either was given ment within 48 h of rash onset. No major differences between treatment groups were evident within the studies or overall early (õ48 h) or late (48 -72 h) after onset of the HZ rash.
(data not shown). Acyclovir versus placebo. Kaplan-Meier plots for time to Methods complete cessation of zoster-associated pain after early and late treatment are illustrated in figure 1A . HRs, 95% CLs, and 48 -72 h after rash onset (figure 1B). HRs, 95% CLs, and
In the fourth placebo-controlled, double-blind trial of the recommedian duration values for zoster-associated pain for early and mended dose of acyclovir [4] , data for most patients were not late treatment are given in table 1; these ratios were also statistiavailable for §6 months because the patients were discharged cally significant, with similar benefits of valaciclovir over from follow-up when they became free of pain for 1 month. Details acyclovir in speeding pain resolution in each subgroup.
of the timings and type of pain assessments in these trials and the way in which times to complete cessation of pain were determined for the present analysis have been provided elsewhere [11] . The valaciclovir dataset (study 2) was from a large multicenter
Discussion
international study in which patient entry was restricted to adults aged §50 years old and treatment was with oral valaciclovir (1000
The intent-to-treat analyses of the duration of zoster-associ- ing the resolution of zoster-associated pain [11] and that the patients were followed for 6 months.
greater systemic acyclovir exposure provided by valaciclovir these results to show that the further benefit of valaciclovir pain and routinely taking into account any differences in demoover that of acyclovir in speeding pain resolution in HZ still graphic variables between treatment groups [14] .
occurs when therapy is delayed up to 72 h after rash onset. The time course of viral replication within neurologic tissues
Since valaciclovir at 1000 mg three times daily for 7 days is (a factor that seems to be of considerable importance both in now the recommended dosage registered in many countries for the pathophysiology of pain during acute HZ and in triggering treatment of HZ, only the data for this regimen in relation to the the central nervous system changes responsible for the profindings for acyclovir are analyzed here.
longed pain after healing of the rash) is unknown and not necessarily the same as the duration of replication within the skin lesions. Since it is the replication within neurons that needs Results to be minimized in order to influence pain, the penetration and activity of antiviral agents within neurons is likely to be of Three hundred sixteen patients were in the acyclovir versus placebo dataset (study 1) and 760 in the valaciclovir versus paramount importance in determining their potential for hastening pain resolution. acyclovir dataset (study 2). The mean age of patients was 52 Results from the present analysis, as well as the finding acyclovir remains appropriate for patients presenting up to 72 h after rash onset. The present study also shows that the greater from a large comparative controlled trial of acyclovir versus netivudine [15] , which failed to show an effect of rash duration concentrations of acyclovir achieved after valaciclovir exposure continue to be an advantage on pain duration even when before treatment on pain duration, indicate that treatment with 
